Enterovirus 71-induced pulomnary oedema and/or neurogenic shock Infections and Infestations Viral infection of unspecified site
Conditions
Interventions
The eligible enrolled patients were randomized to receive either
1. Group A: medical (milrinone) treatment:
Milrinone (Primacor®) was administered to the subjects who met the study criteria. The drug
dosage range of 0.35-0.55ug/kg/min
titrate dose to effect. Therapy was continued for 72 hours.
2. Group B: conventional standard management (supportive acre without milrinone treatment).
All the enrolled subjects received standard med
Sponsors
National Health Research Institutes (NHRI) (Taiwan)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Paediatric patients, EV71 brainstem encephalitis with pulmonary oedema and/or neurogenic shock. 2. EV71 infection was confirmed by isolation of virus or molecular test (real-time PCR) from at least one site (throat swab, stool swab, cerebrospinal fluid (CSF) or other specimens), or serologic assay (neutralizing antibody titre). 3. Stage Definitions Stage IIIB, cardiopulmonary collapse with the occurrence of pulmonary oedema and/or neurogenic shock.
Exclusion criteria
Exclusion criteria: 1. History of congenital heart disease 2. History of pulmonary disorder 3. Known or suspected impairment of immunologic function 4. Known hypersensitivity to any component of Milrinone 5. Prior administration of Milrinone 6. Any condition, which, in the opinion of the investigator, may interfere with the evaluation of the study objectives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy of Milrinone as evaluated by the 1-week mortality in EV71 infected children with pulmonary oedema and/or neurogenic shock. Each enrolled subject was followed with a standard critical care protocol until he or she was discharged from hospital or expired. Evaluation was performed when necessary for all the enrolled subjects during their hospital stays. | — |
Countries
Viet Nam
Outcome results
None listed